International guideline recommendations may not always be extrapolated to developing countries where access to resources is limited. In metastatic castration-sensitive prostate cancer (mCSPC), there have been successful drug and imaging advancements that were addressed in the Prostate Cancer Consensus Conference for Developing Countries for best-practice and limited-resource scenarios.
A total of 24 out of 300 questions addressed staging, treatment, and follow-up for patients with mCSPC both in best-practice settings and resource-limited settings. Responses were compiled and presented in percentage of clinicians supporting each response. Questions had 4-8 options for response.
Recommendations for staging in mCSPC were split but there was consensus that chest x-ray, abdominal and pelvic computed tomography, and bone scan should be used where resources are limited. In both de novo and relapsed low-volume mCSPC, orchiectomy alone in limited resources was favored and in relapsed high-volume disease, androgen deprivation therapy plus docetaxel in limited resources and androgen deprivation therapy plus abiraterone in high-resource settings were consensus. A 3-weekly regimen of docetaxel was consensus among voters. When using abiraterone, a regimen of 1,000 mg plus prednisone 5 mg/d is optimal, but in limited-resource settings, half the panel agreed that abiraterone 250 mg with fatty foods plus prednisone 5 mg/d is acceptable. The panel recommended against the use of osteoclast-targeted therapy to prevent osseous complications. There was consensus that monitoring of patients undergoing systemic treatment should only be conducted in case of prostate-specific antigen elevation or progression-suggestive symptoms.
The treatment recommendations for most topics addressed differed between the best-practice setting and resource-limited setting, accentuating the need for high-quality evidence that contemplates the effect of limited resources on the management of mCSPC.
JCO global oncology. 2021 Apr [Epub]
Fernando Cotait Maluf, Felipe Moraes Toledo Pereira, Pedro Luiz Serrano Uson, Diogo Assed Bastos, Diogo Augusto Rodrigues da Rosa, Evanius Garcia Wiermann, Fábio A Schutz, Fábio Roberto Kater, Fernando Nunes Galvão de Oliveira, Fernando Sabino Marques Monteiro, Fernando Vidigal de Pádua, Francisco Javier Orlandi, Helena Paes de Almeida Saito, Mouna Ayadi, Pamela Salman Boghikian, Ray Manneh Kopp, Ricardo Saraiva de Carvalho, Rodrigo Nogueira de Fogace, Sandro Roberto de Araújo Cavallero, Sergio Aguiar, Vinicius Carreira Souza, Silke Gillessen Sommer
Hospital Israelita Albert Einstein, São Paulo, Brazil., Latin American Oncology Group (LACOG), Rio Grande do Sul, Brazil., Beneficência Portuguesa de São Paulo, São Paulo, Brazil., Orlandi Oncología, Santiago, Chile., Centro de Oncologia Campinas, São Paulo, Brazil., Institut Salah-Azaïz de Cancerologie, Tunis., Fundacion Arturo Lopez Perez, Santiago, Chile., Hospital Ophir Loyol, Belém, Pará, Brazil., Universidad de la República, Montevideo, Uruguay., Oncology Institute of Southern Switzerland (IOSI), Bellinzona and Università della Svizzera Italiana, Lugano, Switzerland.